BIOMERICA INC (BMRA) — 分析摘要
BIOMERICA INC（BMRA）的市值为6.49百万美元，最近一年的营收同比增长了-1.9%。净利润率为-93.6%。当前市盈率为-1.6倍。
核心要点
- 营收同比变化-1.9%
- 净利润率-93.6%
- 市盈率-1.6倍
与IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES板块的其他公司相比，BMRA的营收增长为-1.9%，市盈率为-1.6倍。
BIOMERICA INC (BMRA)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -123.7% — 严重经营亏损
净利率为 -96.5% — 亏损显著
营收较上一期下降 18.5%。
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
行业
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
员工人数
54
总部
IRVINE, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。